This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Neoplasms  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Claudia Hernandez, MD; Sophie M. Worobec, MD; Sujata S. Gaitonde, MD; Monika L. Kiripolsky, MD; Kristen Aquino, BS

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Report of a Case

A 32-year-old man presented with a 2-year history of a pruritic, erythematous dermatitis. A skin biopsy was performed, and he was diagnosed with psoriasis. Treatment was administered with topical corticosteroids, acitretin, UV-B twice per week, and efalizumab, 80 mg, subcutaneous injections each week for 4 months without success. Within 3 months of stopping efalizumab therapy, he developed tumors on his face and ears and presented to the university clinic for evaluation. Other physical findings included alopecic scalp plaques, erythroderma sparing skin folds, palmar and plantar desquamation, erythematous plaques on his back, and no palpable lymphadenopathy.

Abnormal peripheral blood laboratory results included white blood cell count, 15 400/µL (normal, 4000-11 000/µL); absolute lymphocyte count, 9360/µL (normal, 1000-4000/µL); absolute CD3 count, 2215/µL (normal, 1240-1840/µL); absolute CD8 count, 945/µL (normal, 262-787/µL); and lactate dehydrogenase level, 470 U/L . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides
Vito Di Lernia
Arch Dermatol. 2009;145(7):843-844.
EXTRACT | FULL TEXT  

Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides—Reply
Sophie M. Worobec
Arch Dermatol. 2009;145(7):844.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides--Reply
Worobec
Arch Dermatol 2009;145:844-844.
FULL TEXT  

Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides
Di Lernia
Arch Dermatol 2009;145:843-844.
FULL TEXT